Tango Therapeutics (TNGX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.39

Estimate

-$0.35

Surprise

-11.2%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Tango Therapeutics (TNGX) reported a wider loss than forecast — adjusted EPS of -$0.39 against the -$0.35 estimate (a 11.2% shortfall).

• Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 — benzinga, 2026-11-10
• Tango Therapeutics Price Target Adjusted by HC Wainwright & Co. — fiscal.ai, 2026-11-10
• HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 — benzinga, 2026-11-10

TrendMatrix currently rates TNGX Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -11.2% surprise compares with a -0.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$23.71

Price target

$40.57

Stop

$22.05

Upside to target

+71.1%

Reward-to-risk

4.7:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.83B

P/E (fwd)

-12.8

52-week range

$7.49–$34.39

Off 52-week high

31.0%

RSI (14)

40

Volume vs avg

0.35×

Score today

5.4/10